Pioneering therapeutic proteins in hemophilia care through innovative technologies

Thromb Res. 2016 May:141 Suppl 3:S1. doi: 10.1016/S0049-3848(16)30413-3.

Authors

Ingrid Pabinger-Fasching¹, Claude Négrier²

Affiliations

¹ Clinical Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria. Electronic address: Ingrid.pabinger@meduniwien.ac.at.
² Hemophilia Comprehensive Care Center and Hematology Department, Louis Pradel University Hospital, Lyon, France. Electronic address: claude.negrier@chu-lyon.fr.

PMID: 27288062
DOI: 10.1016/S0049-3848(16)30413-3

No abstract available

Publication types

Editorial
Introductory Journal Article

MeSH terms

Clinical Trials as Topic
Factor IX / therapeutic use*
Factor VIII / therapeutic use*
Factor VIIa / therapeutic use*
Hemophilia A / therapy*
Hemophilia B / therapy*
Humans
Recombinant Proteins / therapeutic use

Substances

Recombinant Proteins
Factor VIII
Factor IX
Factor VIIa